- Home
- RGS vs INKT Comparison
RGS vs INKT Comparison
Compare RGS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGS | INKT |
|---|---|---|
| Founded | 1922 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 59.4M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RGS | INKT |
|---|---|---|
| Price | $29.00 | $9.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $39.00 |
| AVG Volume (30 Days) | 4.7K | ★ 15.5K |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $224,485,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.68 | $17.65 |
| P/E Ratio | $12.11 | ★ N/A |
| Revenue Growth | ★ 6.83 | N/A |
| 52 Week Low | $19.31 | $8.48 |
| 52 Week High | $30.93 | $15.35 |
Technical Indicators
Market Signals| Indicator | RGS | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 25.17 |
| Support Level | $26.23 | $8.48 |
| Resistance Level | $29.65 | $12.04 |
| Average True Range (ATR) | 0.59 | 0.55 |
| MACD | -0.05 | -0.29 |
| Stochastic Oscillator | 52.94 | 0.28 |
Price Performance
Historical ComparisonAbout RGS Regis Corporation
Regis Corporation franchises, owns, and operates hair care salons, mainly in North America, with licensed locations in the U.K. Its salons provide haircutting, styling, shampooing and conditioning, hair coloring and related services, and also sell hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, Cost Cutters, First Choice Haircutters and Roosters. Its operating segments are Franchise and Company-Owned, with the majority of its revenue generated from the Franchise segment.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.